Cibus, Inc. (CBUS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Cibus, Inc. is an agricultural biotechnology company utilizing gene editing (RTDS platform) to develop plant traits for major crops, with a current strategic focus on weed management traits for Rice and partner-funded sustainable ingredients. The company operates as a "smaller reporting company" and "non-accelerated filer."
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0.93 million | $1.97 million | $1.38 million |
| Net Loss (GAAP) | $(26.56) million | $(75.95) million | $(55.45) million |
| Net Loss Attributable to Stockholders | $(25.37) million | $(72.26) million | $(48.32) million |
| Diluted EPS | $(0.61) | $(1.88) | $(2.26) |
| Cash and Cash Equivalents | $36.46 million | $36.46 million | $30.02 million |
| Operating Cash Flow | N/A | $(25.43) million | $(30.53) million |
| Current Liabilities | $22.42 million | $22.42 million | N/A |
| Royalty Liability (Related Parties) | $216.49 million | $216.49 million | $182.33 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 42% year-over-year for the six months ended June 30, 2025, driven by collaboration agreements (notably with Procter & Gamble) for Rice and Sustainable Ingredients.
- Goodwill Impairment: The company recorded a non-cash goodwill impairment charge of $21.0 million in Q1 2025 due to a decline in stock price and fair value assessment. This significantly impacted the YTD net loss compared to 2024.
- Expense Reduction: Research and Development (R&D) expenses decreased by 4% YTD, and Selling, General, and Administrative (SG&A) expenses were relatively flat, reflecting ongoing cost reduction initiatives. However, SG&A included a $3.0 million accrual for litigation liability.
- Capital Raises: The company raised approximately $46.4 million in net proceeds during the first half of 2025 through a January registered direct offering and a June public offering.
- Warrant Reclassification: Significant portions of 2024 Common Warrants were reclassified from liabilities to equity following amendments to exercise prices and terms.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the filing date without additional financing. Management expects current cash to fund operations into Q2 2026 but anticipates needing further capital.
- Strategic Pivot: In June 2025, the company announced a streamlined focus on commercializing weed management traits for Rice to preserve capital. It aims to reduce annual net cash burn to approximately $30.0 million by 2026.
- Regulatory Progress: Key milestones include USDA-APHIS designations for Canola traits and regulatory approvals in Ecuador and California for Rice field trials.
- Litigation Risk: A $3.0 million liability was accrued following an unexpected Ninth Circuit Court of Appeals decision regarding insurance coverage proceeds.
- Leadership Change: Rory Riggs resigned as CEO in February 2025; Peter Beetham serves as Interim CEO.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $36.5 million cash balance against the projected $30 million annual burn rate and the timeline for the next capital raise.
- Royalty Liability: Review the $216.5 million related-party royalty liability and the assumptions regarding future subject revenues used to calculate the 16.5% effective yield.
- Goodwill Impairment: Assess the likelihood of further impairment charges given the volatility in the stock price and the high discount rate (47%) used in the fair value calculation.
- Litigation Outcome: Monitor the status of the Ninth Circuit Court of Appeals decision and the potential for the $3.0 million accrual to increase or be resolved.
- Commercialization Timeline: Validate the projected 2027-2028 commercial launch dates for Rice traits and the dependency on partner funding for non-Rice programs.